Clinical Trials Browser

Phase 3 × Pathologic Complete Response × olaparib × Clear all

NCT01844986 2025-12-10

SOLO-1

Phase 3 Active not recruiting

450 enrolled 18 charts 1 FDA

Pathologic Complete Response, Ovarian Neoplasms